DIA 2021 Global Annual Meeting

Back to Agenda

Impact of COVID-19 on Clinical Trial Execution

Session Chair(s)

Mary Jo Lamberti, PhD, MA

Director of Sponsored Research, Research Associate Professor

Tufts Center for the Study of Drug Development, United States

Senior clinical operations executives at major pharmaceutical and biotech companies within the US shared their insights and lessons learned regarding transition to remote and virtual clinical trials due to COVID-19 through in-depth interviews.

Learning Objective : Describe how COVID-19 has impacted the execution of ongoing clinical trials at pharmaceutical and biotech organizations, including remote and virtual approaches adopted; Discuss how the pandemic will influence clinical trial development in the long-term including increased use of telehealth and other technologies.

Speaker(s)

Supporting Clinical Trial Recruitment During COVID-19

Melanie Goodwin, MS, MSc

Pfizer Inc, United States

Director, Patient Recruitment Programs

Decentralized Trials Scale and Commitment Following the Pandemic

Craig H Lipset, MPH

Clinical Innovation Partners, United States

Managing Partner

Have an account?